Brokerages expect Lipocine Inc (NASDAQ:LPCN) to report ($0.26) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Lipocine’s earnings, with estimates ranging from ($0.30) to ($0.21). Lipocine reported earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year over year growth rate of 62.5%. The firm is scheduled to announce its next earnings report on Monday, March 5th.
According to Zacks, analysts expect that Lipocine will report full year earnings of ($1.04) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.00). For the next year, analysts expect that the firm will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.97) to $0.25. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Lipocine.
Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Lipocine in a research note on Friday, December 8th.
Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Lipocine by 39.7% in the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after buying an additional 155,110 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Lipocine by 18.2% in the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after buying an additional 24,000 shares during the last quarter. P.A.W. Capital Corp bought a new stake in shares of Lipocine in the third quarter worth $397,000. Federated Investors Inc. PA increased its stake in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 7,429 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Lipocine in the second quarter worth $300,000. Institutional investors own 22.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Lipocine Inc (LPCN) to Post -$0.26 EPS” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/04/analysts-anticipate-lipocine-inc-lpcn-to-post-0-26-eps.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.